Mylan
1Q Revenues: $2.7 billion (-1%)
1Q Earnings: $87.1 million (+32%)
Comments: Sales in the North America segment were $985.3 million, down 19% primarily due to a combined decrease in the sales of branded products, including EpiPen Auto-Injector, loss of exclusivity of olmesartan and olmesartan HCTZ and the prior year divestiture of certain contract manufacturing assets. Sales in Europe were $146.4 million, up 16% in the quarter, primarily the result of the favorable impact of foreign currency translation in Europe. Sales from new products and favorable volumes were partially offset by slightly lower pricing. Rest of World segment sales were $626.7 million, up 8% due to favorable impact of foreign currency translation and higher sales, partially offset by unfavorable pricing.